A recent study uncovers a pivotal role for the chemokine CXCL5 in cancer cachexia, a condition characterized by severe weight loss, muscle wasting, and widespread inflammation that often accompanies cancer. Led by HJ Kim, the research, published in the Journal of Biomedical Science, shows that neutralizing CXCL5 can lessen several features of this debilitating syndrome.
The investigators describe how CXCL5 contributes to the progression of cancer cachexia and present data suggesting that blocking this chemokine could offer a therapeutic path. Their findings indicate that CXCL5 neutralization dampens inflammatory responses and reduces muscle breakdown, addressing two central symptoms of the condition. By illuminating a key signaling axis in cancer-related wasting, the study opens the door to further exploration of treatments aimed at improving life quality for affected patients.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For suggestions and feedback, please contact us.
Date: December 15, 2025
© www.geneonline.com All rights reserved. Collaborate with us: emailprotected
